TB-500 and Tissue Repair: What the Research Shows

Published August 23, 2026 · Artemis Labs

TB-500 and tissue repair — answer capsule: TB-500 is a synthetic seven-amino-acid peptide, Ac-LKKTETQ, copied from a 43-amino-acid protein called thymosin β4. One 2003 study reported that this fragment promoted repair in aged mice, comparable to the parent. Nearly every other repair paper tested the full-length parent, not the fragment. No published human study of tendon, ligament, or muscle repair exists for either form.

Key findings

• Philp (2003) reported that a seven-amino-acid synthetic peptide, LKKTETQ, promoted repair in aged mice, comparable to the parent molecule. No dose appears in the abstract (PMID 12581423).
• A 2026 review in Am J Sports Med found tissue repair “in preclinical models, but human orthopaedic data are lacking” (PMID 41476424).
• A 2026 scoping review found “67% of identified publications utilized preclinical animal models,” and that claimed recovery benefits “remain unsubstantiated by current human trials” (PMID 42578445).
• A 2024 paper on the fragment itself opens: “the biological effects of TB-500, however, have not been documented” (PMID 38382158).

What is TB-500, and how is it different from thymosin β4?

This distinction decides how you read every study below, so it comes first.

Thymosin β4 (written Tβ4) is a protein the body makes. It is 43 amino acids long and weighs about 4,963 daltons, the unit chemists use for the weight of a single molecule. Its international drug name is timbetasin.

TB-500 is not that protein. It is a synthetic copy of one piece of it: amino acids 17 through 23, the sequence Leu-Lys-Lys-Thr-Glu-Thr-Gln, written LKKTETQ. Seven amino acids, not five, and not 43. It carries an acetyl cap that adds 42 daltons. Full identity: Ac-LKKTETQ-OH, C38H68N10O14, 889.0 g/mol, CAS 885340-08-9, PubChem CID 62707662.

The parent is roughly five and a half times heavier than the fragment. They are related, and they are not the same molecule. A 2010 review described that short sequence as “the central actin-binding domain (aa 17-23)” of thymosin β4 (PMID 20179146). Actin is one of the proteins that gives a cell its internal scaffolding.

Where a study below used the 43-residue parent, this page says so in the same sentence.

What did the one fragment repair study actually find?

The strongest repair result for the seven-amino-acid fragment comes from a single 2003 paper. Its wording, verbatim: “The actin-binding domain of thymosin beta 4 duplicated in a seven-amino acid synthetic peptide, LKKTETQ, was able to promote repair in the aged animals comparable to that observed with the parent molecule” (PMID 12581423).

Two limits travel with that sentence and are easy to lose. The result belongs to the aged mice; the abstract does not claim the fragment matched the parent in the study’s diabetic arm. And the abstract states no dose. It supports a comparison in one animal group, nothing more.

This paper is where the idea that “the fragment works like the parent” comes from. More than twenty years later, it is still the main one.

What do the 2026 sports medicine reviews say?

Four 2026 reviews looked at peptides marketed for recovery. Reviews summarize other people’s studies rather than running new ones, so treat them as a scorecard. All four scored this compound the same way.

Mayfield 2026 (Am J Sports Med) wrote that “TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking, and both remain banned substances in sports.” The same abstract adds that “information regarding the indications, dosing, frequency, and duration of treatment remains unknown” (PMID 41476424). Angiogenesis means the growth of new blood vessels.

Rahman 2026 (JAAOS Glob Res Rev) described the class rather than the compound: “Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation.” Extracellular matrix is the scaffolding between cells; fibroblasts are the cells that build connective tissue. The same abstract adds: “Although preclinical studies are promising, there is a current lack of clinical trials” (PMID 41490200). That is a category summary, not an experiment on TB-500.

Mendias 2026 (Sports Med) is the clearest source on identity, listing the two as separate entries: “Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment).” Its safety line is blunt: “rigorous human safety data are scarce, and there is potential for serious harm to patients” (PMID 41966639).

Tewari 2026 ran a PRISMA scoping review, a formal method for mapping everything published on a question. It reported that “human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs” (PMID 42578445).

What other repair-related studies exist?

One more primary study in this record used a live tissue model, and it used the parent protein. Qu and colleagues (2020) worked in a rabbit ear fat-grafting model, with full-length thymosin β4 premixed into the graft tissue at 5 µg/mL and 10 µg/mL against a plain buffer control (PMID 32144415). Those figures are a concentration in a tissue preparation, not a body dose, and the fragment was never tested that way.

Then there is the metabolism paper, which complicates everything above it. Rahaman and colleagues (2024) followed TB-500 in human serum, in laboratory enzyme systems, and in urine from rats given the compound. It opens: “The biological effects of TB-500, however, have not been documented.” It concluded that the wound-healing activity previously reported for TB-500 “may be due to its metabolite Ac-LKKTE rather than the parent form” (PMID 38382158). A metabolite is what a molecule breaks down into. So it is not settled that the molecule sold as TB-500 is the active species at all.

For how this compound sits alongside others studied in the same area, see our complete guide to recovery and tissue repair peptides. TB-500 is not sold on its own here. It is supplied as part of the BPC-157 and TB-500 research pair, two separate vials at 10 mg each.

What the research does not show

Four gaps, stated plainly.

No human trial of TB-500 exists. Not for repair, not for anything else. Every human study in this molecular family used the full-length 43-amino-acid parent protein, and none of those was about muscle, tendon, or ligament. Our page on TB-500 human trials lists all of them.

There is no primary tendon, ligament, or muscle study of either form in this record. Two independent literature passes looked and found none. That absence is worth sitting with, because tendon and muscle repair is exactly what this compound is marketed around.

Two mechanism claims commonly attached to TB-500 are not supported by anything we hold. “G-actin sequestration” and “stem-cell mobilisation” appear widely, including on older Artemis material. Neither phrase appears in any abstract in our reference list. Until a source says otherwise, we do not print them.

At least one study points the other way. In an irritable bowel syndrome model, Sun et al. (2025) reported that thymosin β4 released by mast cells reduced tight junction proteins and impaired intestinal epithelial barrier integrity in rats and mice, with elevated Tβ4 measured in the colonic mucus of IBS patients (PMID 41278163). Tight junctions are the seals between neighbouring cells. The study examined the body’s own full-length Tβ4, not the TB-500 fragment, and had no human dosing arm. It is a finding about how a disease works, not a toxicity report. We surface it anyway.

One more item, for athletes reading this. The WADA 2026 Prohibited List names, under section S2.3, “Thymosin-β4 and its derivatives e.g. TB-500.” Section S2 substances are prohibited at all times, in and out of competition (WADA Prohibited List).

Frequently asked questions

Has TB-500 been studied for tendon or muscle repair?

No primary study of tendon, ligament, or muscle appears in our verified reference set, for either form. The 2026 reviews say the same thing in their own words: human orthopaedic data are lacking, and claimed musculoskeletal benefits remain unsubstantiated by current human trials.

Is TB-500 the same thing as thymosin β4?

No. TB-500 is a synthetic seven-amino-acid fragment, Ac-LKKTETQ, matching residues 17 to 23 of thymosin β4. The parent protein is 43 amino acids and weighs about five and a half times more. A 2026 review lists them as two separate compounds. See what TB-500 is studied for for the plain-language overview.

Why does the fragment-versus-parent difference matter so much?

Because most of the published repair evidence belongs to the parent protein, and attributing it to TB-500 assumes the fragment behaves the same way. One 2003 study in aged mice supports that assumption in one model. A 2024 paper questions it, finding that a breakdown product, not TB-500 itself, carried the wound-healing activity in its tests.

Does Artemis Labs sell TB-500 by itself?

No. It is supplied inside research blends at 10 mg per vial. No published study has tested any of those combinations.

References

1. Philp, 2003 — repair study of the seven-amino-acid synthetic peptide LKKTETQ and the parent molecule in aged mice. PMID 12581423
2. Sosne, 2010 — review describing LKKTETQ as the central actin-binding domain (aa 17-23) of thymosin β4. PMID 20179146
3. Mayfield, 2026 — narrative review, Am J Sports Med: TB-4 and TB-500 in preclinical models; human orthopaedic data lacking. PMID 41476424
4. Rahman, 2026 — “Therapeutic Peptides in Orthopaedics,” JAAOS Glob Res Rev: class-level wound-healing mechanisms; lack of clinical trials. PMID 41490200
5. Mendias, 2026 — Sports Med: lists Tβ4 and TB-500 as separate compounds; rigorous human safety data scarce. PMID 41966639
6. Tewari, 2026 — PRISMA scoping review of peptide supplements for musculoskeletal recovery and performance. PMID 42578445
7. Rahaman, 2024 — metabolism of TB-500 in human serum, in-vitro enzyme systems, and urine from TB-500-treated rats. PMID 38382158
8. Qu, 2020 — rabbit ear fat-grafting model with full-length thymosin β4 premixed at 5 µg/mL and 10 µg/mL. PMID 32144415
9. Sun YS, et al. Thymosin β4 released by mast cells under stress conditions impairs intestinal epithelial barrier via IL22RA1/JAK1/STAT3 signaling in irritable bowel syndrome. World J Gastroenterol. 2025;31(42):111706. PMID 41278163 · DOI 10.3748/wjg.v31.i42.111706
10. Compound identity: PubChem CID 62707662 (Ac-LKKTETQ-OH, MW 889.0, CAS 885340-08-9) and CID 45382195 / 16132341 (thymosin β4, 43 residues, CAS 77591-33-4). Retrieved 2026-08-23.
11. World Anti-Doping Agency, 2026 Prohibited List, section S2.3. wada-ama.org/en/prohibited-list

Methodology: this page draws only on the abstracts of the peer-reviewed papers listed above and on PubChem identity records, each checked against the primary source. Every citation was re-verified on August 23, 2026.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.